Printer Friendly

New England Business and Technology Association to Host ''The New Biotech/Pharma Research Organization'' As Part of Association's Pipeline Series.

BOSTON -- Participants include Brock Reeve of Life Sciences Insights, Rainer Fuchs, PhD of Biogen Idec, and Ellen Ridge of Genzyme Corporation
WHAT: The New England Business and Technology Association (NEBATA)
 announces that it will host an interactive panel discussion
 entitled "The New Biotech/Pharma Research Organization" as
 part of the Association's Pipeline Series. The session will be
 held on Tuesday, November 9, 2004 at Wilmer Cutler Pickering
 Hale and Dorr, LLP, 60 State Street, Boston, MA.

 "The New Biotech/Pharma Research Organization" will focus on
 addressing key issues and questions that arise for
 biotechnology and pharmaceutical companies such as:

 -- What is the "future state" of research and discovery? What
 will winning companies do differently in one, three, five and
 ten years?

 -- What is driving companies toward that "future state?" How can
 the great goal of "getting more for less" be a realized? How
 will companies be able to get more drugs approved per each
 investment dollar?

 -- What will winning companies do from a technology point of
 view to reach this end point faster and more efficiently? How
 will companies be able to get "spend" aligned with company
 strategies and goals?

WHO: Confirmed participants include:
 Brock Reeve, Vice President, Consulting Practice - Life
 Science Insights (moderator)

 Rainer Fuchs PhD, Vice President, Research Informatics -
 Biogen Idec, Inc.

 Andy Palmer, CIO & Senior Vice President, Operations -
 Infinity Pharmaceuticals

 Ellen Ridge, Vice President - Genzyme Corporation

 David Yee, Head of Knowledge and Information Systems -
 Archemix

WHEN: Tuesday, November 9, 2004
 7:30 a.m. - Registration
 8:00 a.m. - Panel
 10:00 a.m. - Networking Reception

WHERE: Wilmer Cutler Pickering Hale and Dorr, LLP
 60 State Street, Boston, MA


To register for this event, please send contact information to programs@nebata.org. Cost for members is $40; non-members, $80. To receive a press pass, please contact Shannon Altimari at 617-520-7250 or saltimari@weberhsandwick.com.

The NEBATA Pipeline Series is made possible through sponsorship by Wilmer Cutler Pickering Hale and Dorr, LLP, Computer Associates and New Tilt.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 9, 2004
Words:329
Previous Article:European Molecular Biology Laboratory --EMBL-- and Abnova Corporation Announce Partnership Agreement for High-Throughput Monoclonal Antibody...
Next Article:Research And Markets: In Depth Survey Investigating 1,300 Supporters Of English Soccer Clubs Opinions On Key Issues Surrounding The Game And The...


Related Articles
HDMA Healthcare Foundation Releases All-New Biotech Pipeline Analysis; Study of Specific Biotech Therapies Critical to Corporate Planning.
GPC BIOTECH GETS GERMANY PERMITS FOR MONOCLONAL ANTIBODY.
GBC BIOTECH PRESENTS NEW DATA ON EFFICACY OF SATRAPLATIN.
GPC BIOTECH GETS U.S. PATENT FOR ANTI-CANCER CELL INHIBITOR.
ADVISORY/New England Business and Technology Association to Host ''The New Biotech/Pharma Research Organization'' As Part of Association's Pipeline...
GPC BIOTECH/DEBIOPHARM SIGN MHC II ANTAGONISTS LICENSE PACT.
BIOLEX WILL USE LEX TO CREATE LINE FOR KRINGLE NK4.
GIANT AMGEN GROWING.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters